Follow us on:

Linkedin Facebook

Smith & Nephew plc 14.3% Potential Upside Indicated by JP Morgan Cazenove

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Smith & Nephew plc using EPIC/TICKER code (LON:SN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘NEUTRAL’ today by analysts at JP Morgan Cazenove. Smith & Nephew plc are listed in the Health Care sector within UK Main Market. JP Morgan Cazenove have set their target price at 1658 GBX on its stock. This would imply the analyst believes there is now a potential upside of 14.3% from the opening price of 1451 GBX. Over the last 30 and 90 trading days the company share price has decreased 319 points and decreased 372.5 points respectively. The 1 year high stock price is 2023 GBX while the year low share price is currently 1055.01 GBX.

Smith & Nephew plc has a 50 day moving average of 1,728.12 GBX and a 200 day moving average of 1,799.02. There are currently 874,616,025 shares in issue with the average daily volume traded being 4,538,376. Market capitalisation for LON:SN is £12,433,137,756 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Latest Company News

    Smith & Nephew plc

    Smith & Nephew Plc delivers Q3 revenue of $1,412 million, 4% growth

    Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.
    Smith & Nephew plc

    Smith & Nephew Plc transforming into a higher growth and more profitable business

    Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.
    Smith & Nephew

    Smith & Nephew Q1 trading update shows revenue growth and confident outlook

    Smith+Nephew plc (LON:SN, NYSE:SNN) reports Q1 revenue of $1,386 million, up 2.9% underlying. Orthopaedics and Sports Medicine show strong growth. CEO confident in outlook.
    Smith & Nephew plc

    Smith & Nephew reports Q4 revenue of $1,458 million, up 6.4%

    Smith+Nephew plc reports solid financial results for Q4 and full year 2023, showcasing growth in revenue and profit margins. Analyst call scheduled for 27 Feb 2024.
    Smith & Nephew

    Smith+Nephew to attend AAOS 2024, showcasing leading Orthopaedic solutions

    Smith+Nephew plc (LON:SN, NYSE:SNN) will be attending AAOS 2024 Annual Meeting to showcase its innovative medical technology solutions in San Francisco. Learn about their latest products and updates in the orthopaedic field.
    Smith+Nephew

    Smith+Nephew completes acquisition of Agili-C developer, CartiHeal

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.